Following imlunestrant’s approval, Komal Jhaveri, MD, FACP, compares the oral SERD to its counterpart, elacestrant, in terms of composition and trials.

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...

AI-driven decision support can ease oncologists’ workloads and streamline care without reducing autonomy.

A network to connect patients with unused medications with patients in need brought $18 million of free cancer medication ...

Subcutaneous daratumumab is well tolerated, but ongoing immune monitoring is key to managing infection risk in patients with ...

Panelists discuss how the subcutaneous nivolumab data demonstrate reassuring safety with minimal grade 3/4 events, how ...

The use of ctDNA after surgery can provide guidance to patients who may be receiving input on treatment decisions from every ...

C, OCN, discusses planning beyond first-line CDK4/6 inhibitors and supportive care strategies for patients with HR+/HER2– ...

An LED-based intraoral device for photobiomodulation therapy was safe and reduced severe oral mucositis in patients with head ...

Supportive oncology interventions provide a comprehensive approach to oncology, addressing patients’ needs holistically, which start with understanding a patient’s baseline ne ...

Heather Jackson, PhD, APRN, FNP-BC, NEA-BC, FAA-NP, explains the utility of a holistic approach to oncology care. Comprehensive supportive care requires oncology nurses and advanced practice providers ...

IV administration of immune checkpoint inhibitors presents significant operational challenges for oncology practices. As cancer diagnoses increase and patients live longer, requiring sequential ...